MX349146B - Composiciones de peptidos y metodos para tratar lesion pulmonar, asma, anafilaxis, angioedema, sindromes de permeabilidad vascular sistemica, y congestion nasal. - Google Patents
Composiciones de peptidos y metodos para tratar lesion pulmonar, asma, anafilaxis, angioedema, sindromes de permeabilidad vascular sistemica, y congestion nasal.Info
- Publication number
- MX349146B MX349146B MX2013014650A MX2013014650A MX349146B MX 349146 B MX349146 B MX 349146B MX 2013014650 A MX2013014650 A MX 2013014650A MX 2013014650 A MX2013014650 A MX 2013014650A MX 349146 B MX349146 B MX 349146B
- Authority
- MX
- Mexico
- Prior art keywords
- lung injury
- angioedema
- anaphylaxis
- asthma
- methods
- Prior art date
Links
- 206010002198 Anaphylactic reaction Diseases 0.000 title abstract 2
- 208000028185 Angioedema Diseases 0.000 title abstract 2
- 208000004852 Lung Injury Diseases 0.000 title abstract 2
- 206010028735 Nasal congestion Diseases 0.000 title abstract 2
- 206010069363 Traumatic lung injury Diseases 0.000 title abstract 2
- 230000036783 anaphylactic response Effects 0.000 title abstract 2
- 208000003455 anaphylaxis Diseases 0.000 title abstract 2
- 208000006673 asthma Diseases 0.000 title abstract 2
- 231100000515 lung injury Toxicity 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 208000011580 syndromic disease Diseases 0.000 title abstract 2
- 230000009269 systemic vascular permeability Effects 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 102000007640 Inositol 1,4,5-Trisphosphate Receptors Human genes 0.000 abstract 2
- 108010032354 Inositol 1,4,5-Trisphosphate Receptors Proteins 0.000 abstract 2
- 102100038678 Microtubule-associated protein RP/EB family member 3 Human genes 0.000 abstract 2
- 101710099430 Microtubule-associated protein RP/EB family member 3 Proteins 0.000 abstract 2
- 206010030113 Oedema Diseases 0.000 abstract 1
- 206010069351 acute lung injury Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/033—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the internal surface of the plasma membrane, e.g. containing a myristoylation motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Otolaryngology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161496409P | 2011-06-13 | 2011-06-13 | |
| PCT/US2012/042118 WO2012174028A2 (en) | 2011-06-13 | 2012-06-13 | Peptide compositions and methods for treating lung injury, asthma, anaphylaxis, angioedema, systemic vascular permeability syndromes, and nasal congestion |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013014650A MX2013014650A (es) | 2014-01-24 |
| MX349146B true MX349146B (es) | 2017-07-14 |
Family
ID=47357694
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013014650A MX349146B (es) | 2011-06-13 | 2012-06-13 | Composiciones de peptidos y metodos para tratar lesion pulmonar, asma, anafilaxis, angioedema, sindromes de permeabilidad vascular sistemica, y congestion nasal. |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9248198B2 (enExample) |
| EP (1) | EP2717897B1 (enExample) |
| JP (1) | JP6042425B2 (enExample) |
| KR (1) | KR102042015B1 (enExample) |
| CN (2) | CN103608026B (enExample) |
| AU (1) | AU2012271781C1 (enExample) |
| BR (1) | BR112013032108B1 (enExample) |
| CA (1) | CA2838662C (enExample) |
| DK (1) | DK2717897T3 (enExample) |
| ES (1) | ES2633343T3 (enExample) |
| IL (1) | IL229771B (enExample) |
| MX (1) | MX349146B (enExample) |
| PL (1) | PL2717897T3 (enExample) |
| WO (1) | WO2012174028A2 (enExample) |
| ZA (1) | ZA201309161B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2633343T3 (es) * | 2011-06-13 | 2017-09-20 | The Board Of Trustees Of The University Of Illionis | Composiciones de péptidos y métodos para tratar lesión pulmonar, asma, anafilaxis, angioedema, síndromes de permeabilidad vascular sistémica y congestión nasal |
| CN107427549B (zh) * | 2015-03-02 | 2022-01-11 | 伊利诺伊大学受托管理委员会 | 用于抑制血管生成的肽 |
| CN110128506B (zh) * | 2019-05-22 | 2021-03-30 | 中国药科大学 | 一种寡肽及其应用 |
| CN110664990B (zh) * | 2019-11-07 | 2021-03-16 | 江南大学 | 一种trpc1肽类分子在制备治疗病毒感染引起的炎症的药物中的应用 |
| TW202204375A (zh) * | 2020-04-15 | 2022-02-01 | 美商寇峇有限公司 | 治療冠狀病毒感染之方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US6093740A (en) * | 1997-04-30 | 2000-07-25 | Eli Lilly And Company | Therapeutic treatment for skin disorders |
| GB9718609D0 (en) * | 1997-09-02 | 1997-11-05 | Imp College Innovations Ltd | Fusion protein |
| US7368430B2 (en) * | 2003-11-06 | 2008-05-06 | Research Development Foundation | Selective inhibitors of nuclear factor-κB activation and uses thereof |
| KR101206843B1 (ko) * | 2003-12-03 | 2012-11-30 | 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 | 튜불린 저해제 |
| AU2006292203A1 (en) * | 2005-09-21 | 2007-03-29 | Dask Technologies, Llc | Methods and compositions for organ and tissue functionality |
| KR101399175B1 (ko) * | 2006-07-21 | 2014-06-19 | 푼다싸웅 지 앙빠루 아 뻬스끼자 두 에스따두 지 싸웅 파울루 - 에피아뻬에에씨뻬 | 항염증성 및 항알레르기성 시클릭 펩티드 |
| US7585865B2 (en) * | 2006-07-21 | 2009-09-08 | The Penn State Research Foundation | Protein kinase C zeta inhibition to treat vascular permeability |
| KR20200075044A (ko) * | 2008-01-22 | 2020-06-25 | 아라임 파마슈티칼즈, 인크. | 조직 손상 관련 질환 및 장애를 예방 및 치료하기 위한 조직 보호 펩티드 및 펩티드 유사체 |
| FR2940032B1 (fr) | 2008-12-23 | 2013-08-09 | Seb Sa | Panier de cuisson d'aliments et systeme de cuisson correspondant |
| IT1392567B1 (it) * | 2008-12-24 | 2012-03-09 | Bioindustry Park Del Canavese S P A | Uso di un peptide derivato da er-alfa per il ripristino della sensibilita' a composti antiestrogenici in cellule di tumore mammario |
| US20100190691A1 (en) | 2009-01-27 | 2010-07-29 | Trojan Technologies, Ltd | Delivery of nucleic acids using cell-penetrating peptides |
| ES2633343T3 (es) * | 2011-06-13 | 2017-09-20 | The Board Of Trustees Of The University Of Illionis | Composiciones de péptidos y métodos para tratar lesión pulmonar, asma, anafilaxis, angioedema, síndromes de permeabilidad vascular sistémica y congestión nasal |
-
2012
- 2012-06-13 ES ES12800251.6T patent/ES2633343T3/es active Active
- 2012-06-13 BR BR112013032108-3A patent/BR112013032108B1/pt not_active IP Right Cessation
- 2012-06-13 CN CN201280029277.6A patent/CN103608026B/zh active Active
- 2012-06-13 MX MX2013014650A patent/MX349146B/es active IP Right Grant
- 2012-06-13 WO PCT/US2012/042118 patent/WO2012174028A2/en not_active Ceased
- 2012-06-13 PL PL12800251T patent/PL2717897T3/pl unknown
- 2012-06-13 DK DK12800251.6T patent/DK2717897T3/en active
- 2012-06-13 CA CA2838662A patent/CA2838662C/en active Active
- 2012-06-13 AU AU2012271781A patent/AU2012271781C1/en active Active
- 2012-06-13 CN CN201610552695.3A patent/CN106188232B/zh active Active
- 2012-06-13 EP EP12800251.6A patent/EP2717897B1/en active Active
- 2012-06-13 US US14/105,385 patent/US9248198B2/en active Active
- 2012-06-13 KR KR1020137033193A patent/KR102042015B1/ko not_active Expired - Fee Related
- 2012-06-13 JP JP2014515930A patent/JP6042425B2/ja not_active Expired - Fee Related
-
2013
- 2013-12-03 IL IL229771A patent/IL229771B/en active IP Right Grant
- 2013-12-05 ZA ZA2013/09161A patent/ZA201309161B/en unknown
-
2014
- 2014-03-31 US US14/230,642 patent/US8912139B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2633343T3 (es) | 2017-09-20 |
| US9248198B2 (en) | 2016-02-02 |
| IL229771B (en) | 2019-07-31 |
| US8912139B2 (en) | 2014-12-16 |
| WO2012174028A3 (en) | 2013-02-21 |
| DK2717897T3 (en) | 2017-07-17 |
| EP2717897B1 (en) | 2017-04-19 |
| MX2013014650A (es) | 2014-01-24 |
| EP2717897A4 (en) | 2015-01-07 |
| BR112013032108A2 (pt) | 2016-11-22 |
| EP2717897A2 (en) | 2014-04-16 |
| US20140213505A1 (en) | 2014-07-31 |
| JP6042425B2 (ja) | 2016-12-14 |
| CN106188232B (zh) | 2020-01-07 |
| PL2717897T3 (pl) | 2017-09-29 |
| CN103608026B (zh) | 2016-08-24 |
| CA2838662A1 (en) | 2012-12-20 |
| AU2012271781B2 (en) | 2017-02-16 |
| CN103608026A (zh) | 2014-02-26 |
| CN106188232A (zh) | 2016-12-07 |
| WO2012174028A2 (en) | 2012-12-20 |
| ZA201309161B (en) | 2015-03-25 |
| AU2012271781A1 (en) | 2014-01-09 |
| KR102042015B1 (ko) | 2019-11-07 |
| US20140155314A1 (en) | 2014-06-05 |
| BR112013032108B1 (pt) | 2021-10-26 |
| KR20140056185A (ko) | 2014-05-09 |
| CA2838662C (en) | 2018-07-24 |
| AU2012271781C1 (en) | 2017-09-21 |
| JP2014518211A (ja) | 2014-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ730763A (en) | Methods of treating a tauopathy | |
| WO2012058393A3 (en) | Dkk1 antibodies and methods of use | |
| HK1208151A1 (en) | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer | |
| NZ725347A (en) | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer | |
| PH12015500390A1 (en) | Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis | |
| IN2012DN02368A (enExample) | ||
| WO2012149356A3 (en) | Anti-cd40 antibodies and methods of use | |
| MY195289A (en) | Anti IL-36R Antibodies | |
| WO2014025771A3 (en) | Methods and compositions for inactivating enveloped viruses | |
| WO2012031250A3 (en) | Compositions for labeling nerves and methods of use | |
| WO2014059442A3 (en) | Antibody based reagents that specifically recognize toxic oligomeric forms of tau | |
| MX2014005462A (es) | Moduladores de trasportadores de casete enlazante de atp. | |
| MX2014001372A (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer pancreatico. | |
| WO2009136352A8 (en) | Anti-angiogenic compounds | |
| WO2011121576A3 (en) | Immunogenic proteins and compositions for the treatment and prevention of streptococcus agalactiae | |
| WO2012010974A3 (en) | Combination pharmaceutical compositions and method of treatment of vertigo, kinetosis and vegetative-vascular dystonia | |
| MX349146B (es) | Composiciones de peptidos y metodos para tratar lesion pulmonar, asma, anafilaxis, angioedema, sindromes de permeabilidad vascular sistemica, y congestion nasal. | |
| WO2011116212A3 (en) | Bone morphogenetic protein receptor binding agents and methods of their use | |
| WO2013023151A3 (en) | Compositions and methods for treating celiac sprue disease | |
| EP4556071A3 (en) | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer | |
| WO2007106915A8 (en) | Antibodies to egfl7 and methods for their use | |
| WO2009092052A3 (en) | Methods and compositions for treating polyps | |
| WO2013111012A3 (en) | Methods and compositions for therapeutic agents | |
| WO2014039074A3 (en) | Therapeutic compositions and related methods | |
| WO2012136534A3 (de) | Verwendung eines mittels aus antikörpern und/oder insulin-like growth factor-antagonisten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |